ADMP
Adamis Pharmaceuticals Corporation [ADMP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ADMP Stock Summary
In the News
Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2023 Earnings Conference Call May 15, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to Adamis Pharmaceuticals First Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q4 2022 Results Conference Call March 16, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Dr. Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to the Adamis Pharmaceuticals Full Year 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website .
Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News
It's an unusual day for Adamis Pharmaceuticals (NASDAQ: ADMP ) stock traders, to say the least. That's because the company recently announced its intent to acquire DMK Pharmaceuticals.
How to Diversify Your Penny Stock Investments
Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Robert Uhl - Westwicke Partners David Marguglio - Co-Founder, CEO, President & Director David Benedicto - CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals' Third Quarter 2020 Financial Results Conference Call. [Operator Instructions].
10 Top Penny Stocks To Buy For Uner $1 Right Now
Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Good Penny Stocks To Buy Now? 7 Under $1 To Watch This Week
Penny stocks to watch under $1 right now. The post Good Penny Stocks To Buy Now?
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Adamis Pharmaceuticals recently provided an update on Tempol's Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes.
Adamis Pharmaceuticals Corporation (ADMP) CEO David J. Marguglio on Q2 2022 Results - Earnings Call Transcript
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke David J. Marguglio - Chief Executive Officer David Benedicto - Chief Financial Officer Ron Moss - Chief Medical Officer Conference Call Participants Operator Greetings and welcome to the Adamis Pharmaceuticals' Second Quarter 2022 Financial Results Conference Call.
ADMP Financial details
ADMP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 27.02 | 29.06 | 14.91 | 1.07 | 2.22 | |
| Net income per share | -69.86 | -38.52 | -44.57 | -16.8 | -12.24 | |
| Operating cash flow per share | -58.49 | -26.13 | -18.86 | -18.35 | -12.1 | |
| Free cash flow per share | -64.82 | -29.9 | -19.72 | -18.94 | -12.42 | |
| Cash per share | 34.51 | 11.58 | 6.19 | 11.28 | 0.51 | |
| Book value per share | 83.62 | 47.36 | 3.16 | 12.57 | -0.38 | |
| Tangible book value per share | 46.28 | 22.7 | -3.3 | 12.57 | -0.38 | |
| Share holders equity per share | 83.62 | 47.36 | 3.16 | 12.57 | -0.38 | |
| Interest debt per share | 4.91 | 5.52 | 6.33 | 0.34 | 0.18 | |
| Market cap | 87.94M | 37.31M | 37.63M | 87.22M | 25.37M | |
| Enterprise value | 71.25M | 32.58M | 37.64M | 64.69M | 24.63M | |
| P/E ratio | -2.25 | -1.27 | -0.76 | -2.52 | -0.97 | |
| Price to sales ratio | 5.83 | 1.69 | 2.28 | 39.49 | 5.33 | |
| POCF ratio | -2.69 | -1.88 | -1.8 | -2.31 | -0.98 | |
| PFCF ratio | -2.43 | -1.64 | -1.72 | -2.24 | -0.95 | |
| P/B Ratio | 1.88 | 1.04 | 10.76 | 3.37 | -31.39 | |
| PTB ratio | 1.88 | 1.04 | 10.76 | 3.37 | -31.39 | |
| EV to sales | 4.72 | 1.47 | 2.28 | 29.29 | 5.18 | |
| Enterprise value over EBITDA | -1.97 | -1.26 | -1.12 | -2.11 | -1.01 | |
| EV to operating cash flow | -2.18 | -1.64 | -1.8 | -1.71 | -0.95 | |
| EV to free cash flow | -1.97 | -1.43 | -1.72 | -1.66 | -0.93 | |
| Earnings yield | -0.44 | -0.79 | -1.31 | -0.4 | -1.03 | |
| Free cash flow yield | -0.41 | -0.61 | -0.58 | -0.45 | -1.05 | |
| Debt to equity | 0.06 | 0.11 | 1.96 | 0.03 | -0.42 | |
| Debt to assets | 0.04 | 0.09 | 0.22 | 0.02 | 0.03 | |
| Net debt to EBITDA | 0.46 | 0.18 | 0 | 0.74 | 0.03 | |
| Current ratio | 2.23 | 1.36 | 0.63 | 3.14 | 0.81 | |
| Interest coverage | -250.14 | -235.51 | -233.22 | -4.82K | -567.9 | |
| Income quality | 0.84 | 0.68 | 0.42 | 0.82 | 0.98 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.25 | 0.47 | 0.5 | 5.1 | 2.18 | |
| Intangibles to total assets | 0.36 | 0.39 | 0.23 | 0 | 0 | |
| Capex to operating cash flow | 0.11 | 0.14 | 0.05 | 0.03 | 0.03 | |
| Capex to revenue | -0.23 | -0.13 | -0.06 | -0.55 | -0.14 | |
| Capex to depreciation | -1.14 | -0.97 | -0.26 | -0.85 | -0.46 | |
| Stock based compensation to revenue | 0.43 | 0.27 | 0.27 | 0.9 | -0.07 | |
| Graham number | 362.55 | 202.59 | 56.26 | 68.93 | 10.2 | |
| ROIC | -0.79 | -0.69 | -3.11 | -1.18 | 203.84 | |
| Return on tangible assets | -1.04 | -1.01 | -2.08 | -0.9 | -2.4 | |
| Graham Net | 18.11 | -0.73 | -16.37 | 7.5 | -4.31 | |
| Working capital | 14.23M | 3.67M | -7.4M | 23.98M | -2.12M | |
| Tangible asset value | 25.84M | 17.27M | -3.66M | 25.88M | -808.07K | |
| Net current asset value | 14.12M | 2.07M | -14.85M | 22.79M | -2.47M | |
| Invested capital | 0.06 | 0.11 | 1.96 | 0.03 | -0.42 | |
| Average receivables | 992.63K | 1.52M | 1.49M | 3.5M | 3.49M | |
| Average payables | 3.54M | 4.22M | 3.88M | 3.62M | 5.85M | |
| Average inventory | 2.55M | 2.67M | 2.59M | 1.77M | 828.69K | |
| Days sales outstanding | 27.95 | 30.99 | 24.14 | 975.02 | 83.27 | |
| Days payables outstanding | 155.37 | 100.63 | 85.57 | 199.39 | 468.23 | |
| Days of inventory on hand | 122.15 | 48.6 | 76.36 | 22.23 | 73.08 | |
| Receivables turnover | 13.06 | 11.78 | 15.12 | 0.37 | 4.38 | |
| Payables turnover | 2.35 | 3.63 | 4.27 | 1.83 | 0.78 | |
| Inventory turnover | 2.99 | 7.51 | 4.78 | 16.42 | 4.99 | |
| ROE | -0.84 | -0.81 | -14.12 | -1.34 | 32.42 | |
| Capex per share | -6.33 | -3.77 | -0.85 | -0.59 | -0.32 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.7 | 1 | 0.67 | 0 | 1.28 | |
| Net income per share | -2.05 | -1.59 | 0.03 | -3.34 | 0.05 | |
| Operating cash flow per share | -3.5 | -0.71 | -0.71 | -1 | 0 | |
| Free cash flow per share | -3.6 | -0.75 | -0.71 | -1 | 0 | |
| Cash per share | 1.13 | 0.5 | 1.42 | 0.25 | 943.14 | |
| Book value per share | 1.33 | -0.38 | -4.43 | -4.6 | -702.64 | |
| Tangible book value per share | 1.33 | -0.38 | -4.43 | -4.6 | -702.64 | |
| Share holders equity per share | 1.33 | -0.38 | -4.43 | -4.6 | -702.64 | |
| Interest debt per share | 0.34 | 0.04 | 1.3 | 0.08 | 8.94 | |
| Market cap | 29.76M | 25.39M | 17.72M | 6.19M | 4.87M | |
| Enterprise value | 27.77M | 24.65M | 14.87M | 5.71M | -6.6B | |
| P/E ratio | -1.69 | -1.87 | 61.77 | -0.18 | 3.5 | |
| Price to sales ratio | 19.77 | 11.81 | 12.19 | 891.61 | 0.54 | |
| POCF ratio | -3.97 | -16.68 | -11.45 | -2.41 | 0 | |
| PFCF ratio | -3.86 | -15.74 | -11.45 | -2.41 | 0 | |
| P/B Ratio | 10.46 | -31.42 | -1.83 | -0.52 | 0 | |
| PTB ratio | 10.46 | -31.42 | -1.83 | -0.52 | 0 | |
| EV to sales | 18.45 | 11.46 | 10.23 | 822.07 | -727.86 | |
| Enterprise value over EBITDA | -7.07 | -5.29 | -3.87 | -1.36 | 2.02K | |
| EV to operating cash flow | -3.7 | -16.2 | -9.61 | -2.22 | 0 | |
| EV to free cash flow | -3.6 | -15.28 | -9.61 | -2.22 | 0 | |
| Earnings yield | -0.15 | -0.13 | 0 | -1.38 | 0.07 | |
| Free cash flow yield | -0.26 | -0.06 | -0.09 | -0.41 | 0 | |
| Debt to equity | 0.15 | -0.42 | -0.03 | -0.01 | -0.01 | |
| Debt to assets | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 | |
| Net debt to EBITDA | 0.51 | 0.16 | 0.74 | 0.11 | 2.02K | |
| Current ratio | 1.14 | 0.81 | 0.58 | 0.23 | 0.58 | |
| Interest coverage | -15.52 | 17.09 | -2.48 | -244.09 | 110.81 | |
| Income quality | 1.7 | 0.46 | 0.17 | 0.3 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 580.72 | 0 | |
| Research and developement to revenue | 1.31 | 0.4 | 0.9 | 54.28 | 0.05 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.06 | 0 | 0 | 0 | |
| Capex to revenue | -0.14 | -0.04 | 0 | 0 | 0 | |
| Capex to depreciation | -0.52 | -0.25 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.05 | -0.15 | 0.05 | 7.52 | 0 | |
| Graham number | 7.83 | 3.67 | 1.81 | 18.59 | 27.91 | |
| ROIC | -1.28 | 35.34 | -0.01 | 1.27 | 0 | |
| Return on tangible assets | -0.36 | -0.31 | 0.01 | -1.81 | 0 | |
| Graham Net | -2.41 | -4.31 | -7.01 | -6.07 | -980.32 | |
| Working capital | 1.21M | -2.12M | -5.4M | -11.56M | -5.59B | |
| Tangible asset value | 2.85M | -808.07K | -9.68M | -11.83M | -4.96B | |
| Net current asset value | 796.27K | -2.47M | -11.21M | -13.12M | -6.05B | |
| Invested capital | 0.15 | -0.42 | -0.03 | -0.01 | -0.01 | |
| Average receivables | 1.26M | 1.32M | 553.09K | 20.07K | 9.49K | |
| Average payables | 4.91M | 6.62M | 8.86M | 10.57M | 4.99B | |
| Average inventory | 766.32K | 1.17M | 951.57K | 664.36K | 331.81M | |
| Days sales outstanding | 92.89 | 45.4 | 1.31 | 245.84 | 0 | |
| Days payables outstanding | 289.39 | 287.85 | 492.31 | 2.83K | 0 | |
| Days of inventory on hand | 59.68 | 44.92 | 33.44 | 165.45 | 0 | |
| Receivables turnover | 0.97 | 1.98 | 68.63 | 0.37 | 0 | |
| Payables turnover | 0.31 | 0.31 | 0.18 | 0.03 | 0 | |
| Inventory turnover | 1.51 | 2 | 2.69 | 0.54 | 0 | |
| ROE | -1.55 | 4.21 | -0.01 | 0.73 | 0 | |
| Capex per share | -0.1 | -0.04 | 0 | 0 | 0 |
ADMP Frequently Asked Questions
What is Adamis Pharmaceuticals Corporation stock symbol ?
Adamis Pharmaceuticals Corporation is a US stock , located in San diego of Ca and trading under the symbol ADMP
What is Adamis Pharmaceuticals Corporation stock quote today ?
Adamis Pharmaceuticals Corporation stock price is $- today.
Is Adamis Pharmaceuticals Corporation stock public?
Yes, Adamis Pharmaceuticals Corporation is a publicly traded company.
Company Profile
- Volume Average 3.11M
- Market Capitalization 7.25M
- Employee 11
- CEO Dr. Ebrahim Versi M.D., Ph.D.
- Headquarters San Diego,CA,US
- IPO Date 1995-08-14
-
Website
https://www.adamispharmaceuticals.com 
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
